The MedTech segment reported outperforming expectations in July 2025.
2 reports, 1 independent
Updated Jul 21
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The MedTech segment reported outperforming expectations in July 2025.
Who's involved
What this event is mainly aboutKeep exploring
Part of
Domination in medical technology industry involving Intuitive Surgical, Johnson & Johnson, and Stryker.Also in this story
- Intuitive Surgical and Johnson & Johnson are competing in the robotic surgery market, with J&J maintaining a global office in Santa Clara.
- Intuitive Surgical and Stryker Corporation are highlighted as medtech giants, with new deals and adoption rates driving competition in the operating room.
The entities involved
-
Johnson & Johnson
U.S multinational medical devices, pharmaceutical and consumer packaged goods manufacturer
Related events
- Johnson & Johnson's MedTech segment reported sales below expectations and is facing an investigation into federal securities law violations.
- Johnson & Johnson's MedTech segment missed Q3 estimates, while JNJ's P/E ratio was compared against Eli Lilly and Pfizer.
- Analyst targets are being lowered amid new entrants challenging market dominance for medical technology companies.
Coverage
Newest first; wire copies grouped- ZacksShould J&J Stock Be in Your Portfolio After Q2 Beat & Guidance Raise? Johnson & Johnson JNJ delivered strong second-quarter 2025 results, with both the top and bottom lines exceeding expectations. De
- Unknown outlet